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Mounting evidence suggests that inflammation is the key
factor in the pathogenesis of various ocular surface
diseases, with a complex interplay of genetic,
environmental, and psychosocial factors. Management of
these conditions is often challenging. Topical
corticosteroids, with their associated side effects, are the
mainstay of current treatments for patients with vision
threatening disease. Ciclosporin A is an immunomodulator
that specifically inhibits T lymphocyte proliferation.
Recently, a topical ciclosporin preparation was approved
by the US Food and Drug Administration and became
available for use in ophthalmology. Given the increasing
use of ciclosporin eye drops, the goal of this article is to
provide the reader with an overview of the well established
uses of ciclosporin and to help refine the questions that
should be addressed by future investigations.
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T
he ocular surface encompasses the entire
epithelial surface of the cornea, limbus, and
conjunctiva. The primary purpose of this
functional unit is to maintain corneal clarity, a
critical component of the eye’s optical system.
Even a small change in corneal clarity, such as a
less than adequate tear film, can lead to visual
disturbances.
Ocular surface diseases are a large group of
disorders with a variety of aetiologies, symptoms,
and clinical findings. These disorders range from
simple meibomian gland dysfunction, with excel-
lent prognosis, to Stevens-Johnson syndrome,
which can cause permanent scarring of the
conjunctiva, loss of corneal transparency and hence
loss of vision, with considerable impairment in
quality of life. Ironically, most patients with ocular
surface disease have a healthy posterior segment
with otherwise favourable visual prognosis.
Whatever the initial aetiological factor of
ocular surface disease, once the disease has
developed, inflammation becomes the key
mechanism of injury to the ocular surface.1 2
There is a diversity of initiating insults, such as
tear film insufficiency, chemical injury, or
hypersensitivity mechanisms. When present,
inflammation is augmented by mediators
released from damaged cells and invading
leucocytes. Hence, eyes with ocular surface
disease may be trapped in a vicious cycle of
inflammation and resultant injury.
Currently, the anti-inflammatory treatment of
ocular surface disorders mainly relies on topical
or systemic corticosteroids, which carry the risk
of serious side effects. A topical ciclosporin A
(CsA) preparation has recently become commer-
cially available. CsA is an established immuno-
modulating drug that was originally used to
prevent rejection after organ or tissue transplan-
tation. Systemic CsA has also been employed as a
treatment for a variety of autoimmune diseases,
including those with ocular involvement.3–5
CsA is a neutral, hydrophobic, cyclic undeca-
peptide metabolite of the fungus Tolypocladium
inflatum. Its major clinical effect is the perturba-
tion of expression of interleukin-2 (IL-2) by
helper T cells, preventing the proliferation of T
cells.3 CsA was discovered in the early 1970s as
an antifungal agent. Later, owing to its lack of
bone marrow toxicity,6 it assumed a leading role
in solid organ transplant surgery,7 with drama-
tically improved patient prognosis. In ophthal-
mology, topically applied CsA in various oil based
solvents was first used to inhibit experimental
corneal allograft reaction in the early 1980s8 9;
this was followed by human studies.10 Later, the
drug proved useful for patients with various
inflammatory ocular surface disorders.11 12
The main problems with the eye drop prepara-
tion of CsA were sterility, pH, particles, and its
lipophilic properties. A licensed topical CsA (0.2%
in ointment form, Optimmune, Schering-Plough)
has been available in veterinary ophthalmology for
the treatment of canine keratoconjunctivitis sicca,
but the introduction of a similar preparation for
human pharmacy (0.05% eye drop form, Restasis,
Allergan Inc) did not occur until April 2003. This
preparation has now been approved by the Food
and Drug Administration for use in the treatment
of dry eye condition in humans. Given the
increasing use of this product in patients by
practising ophthalmologists for various indica-
tions, the goal of this analysis was to evaluate the
peer reviewed published scientific literature, to
define well established uses of CsA eye drops, and
to help refine the important questions to be
addressed by future investigations.
DRY EYE SYNDROME
Dry eye syndrome is a common disorder of the
tear film that results in epithelial damage and
the disruption of normal homeostasis at the
ocular surface. Clinical features of dry eye
syndrome include an unstable tear film, ocular
surface inflammation, and epitheliopathy, result-
ing in symptoms ranging from discomfort to
blindness.13
Abbreviations: CsA, ciclosporin A; IL-2, interleukin-2;
PUK, peripheral ulcerative keratitis
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Dry eye syndrome is widespread with as many as 25% of
patients visiting ophthalmologists reporting dry eye symp-
toms.14 The current understanding of the pathogenesis of dry
eye disease has proceeded from the mere recognition of a lack
of, or altered quality of, tears to recognition of inflammation
as the key pathogenetic mechanism, whether from a systemic
autoimmune disease or a local autoimmune event.15
Inadequate tear production and low tear clearance, for
whatever reason, lead to chronic inflammation of the ocular
surface, mediated mainly by T lymphocytes.15 Moreover, the
conjunctival T cell subpopulations do not differ significantly
in Sjögren’s syndrome and non-Sjögren’s syndrome patients
with dry eye.16 Androgens also represent an important trophic
factor for the ocular surface, and their deficiency predisposes
to inflammation from both lacrimal and meibomian gland
dysfunction.17 Immune based inflammation can therefore
interconnect and negatively reinforce these different patho-
genetic mechanisms, resulting in a vicious cycle and
subsequent ocular surface damage.
The traditional approach to treating dry eye has been to
lubricate the ocular surface by replacing or conserving the
patient’s tears, without correcting the underlying disease
process. Yet these treatments do not directly address the
ocular surface inflammation.
Anti-inflammatory therapies are considered for patients
with moderate to severe dry eye syndrome who continue to
have symptoms or who have evidence of corneal disease on
aqueous enhancement therapies. Several clinical studies have
shown topical corticosteroids to improve both signs and
symptoms of dry eye.18 19
In preliminary studies on small groups of patients,
treatment with topical CsA improved the signs and symp-
toms of dry eye syndrome.20–22 Evidence of the inflammatory
nature of dry eye syndrome and the success of the
preliminary investigations led to large scale multicentre,
randomised, placebo controlled, double masked, dose ran-
ging clinical trials of the efficacy and safety of topical CsA
therapy in moderate to severe dry eye syndrome. A CsA oil in
water emulsion formulation significantly improved the
ocular signs and symptoms of moderate to severe dry eye in
patients with or without Sjögren’s syndrome, and was found
to be safe and well tolerated.23 In this phase 2 study, of the
four different CsA dosing regimens (0.05%, 0.1%, 0.2%, and
0.4%), the 0.05% dose gave the most consistent improvement
in symptoms. Following this study, the efficacy and safety of
topical 0.05% and 0.1% CsA were compared with vehicle in
patients with moderate to severe dry eye syndrome.24 As in
the phase 2 study, both formulations were reported to be safe
and effective, and the 0.05% formulation produced signifi-
cantly greater improvements in signs (that is, corneal
staining and Schirmer values) and symptoms (blurred vision,
need for concomitant artificial tears, and the physician’s
evaluation of global response to treatment). The 877 patients
(293 in the 0.05% CsA group, 292 in the 0.1% group, and 292
in the vehicle group) in the study were treated for 6 months.
In addition, a subset of patients from the phase 3 study
underwent conjunctival biopsy before and after treatment
with topical CsA, in order to investigate the effect of
treatment on ocular surface histopathology. An increase in
goblet cell counts was reported in association with clinical
improvement.25 Reduced numbers of activated lymphocytes
in conjunctiva 26 and a decrease in IL-6 in conjunctival
epithelium27 were also observed.
Evidence obtained from these studies supports the efficacy
of topical CsA treatment through its immunomodulatory
action and a possible direct lacrimogenic effect as shown in a
canine model in reversing inflammation of the ocular surface
and lacrimal glands and in improving the signs and
symptoms of dry eye syndrome in patients with or without
Sjögren’s syndrome. However, the optimal dosing and
required duration of treatment are not known.
VERNAL KERATOCONJUNCTIVITIS
Vernal keratoconjunctivitis is a severe, chronic allergic
disorder, seen primarily in young males, often with a history
of atopy. The hallmark sign of vernal keratoconjunctivitis is
giant papillae on the upper tarsal conjunctiva, although in
some patients limbal oedema may be predominant.
The disease tends to be self limited and frequently
disappears after the teen age period, but a chronic, more
severe form of disease can be seen in adults. In certain
countries it is the most common form of conjunctivitis.28
The management of vernal keratoconjunctivitis is deter-
mined by the severity of involvement. Mast cell stabilisers are
generally considered effective, based on studies from Europe
and North America.29–31 However, results from the Middle
East and Africa have not consistently shown benefit.32–34
Vision threatening corneal complications include central
epithelial keratitis and shield-like ulcers. Topical steroids
usually alleviate the acute symptoms,32 but unsupervised
treatment leads to glaucoma and cataract formation in a
significant proportion of patients.35 Particularly in the
developing countries, vernal keratoconjunctivitis is consid-
ered a potentially blinding disease.36 37 The search for new,
effective, safe treatments of this potentially blinding disease
continues. Recently, a 2 week trial of topical 0.01% mitomy-
cin C, four times daily, proved safe and effective in the
treatment of patients with severe, blinding vernal kerato-
conjunctivitis resistant to topical steroids.38
The immunopathogenetic mechanism is complex and
involves an IgE mediated immediate hypersensitivity
response as well as a Th2 type of immune reaction.39 40
Multiple studies on the efficacy of topical CsA for treating
vernal keratoconjunctivitis have consistently shown a bene-
ficial effect of the drug.41–46 The improvement produced by
topical CsA usually took an average of 2 weeks using 1% or
2% CsA in oil solvents, four times daily. The duration of
treatment depends on the activity of the inflammation. No
major adverse effect was reported, except for mild burning
and stinging. A rebound phenomenon occurred soon after
discontinuation of the treatment, indicating the need for a
slow taper.41
ATOPIC KERATOCONJUNCTIVITIS
Atopic keratoconjunctivitis is a bilateral, inflammatory
external ocular disease that manifests in the context of
atopic dermatitis. There appears to be an increasing incidence
of atopic dermatitis worldwide in recent years,47 possibly
because of increased exposure to airborne allergens or
irritants. About 25% to 40% of patients with atopic dermatitis
have ocular involvement.48
Atopic keratoconjunctivitis is the most important of the
allergic ocular surface disorders, because of its chronic course
and frequent corneal complications that can lead to
permanent loss of vision.49–51 Unlike vernal keratoconjuncti-
vitis, atopic keratoconjunctivitis can involve both upper and
lower palpebral conjunctivae, with resultant scarring indis-
tinguishable from other causes of cicatrising conjunctivitis.
The pathogenesis of atopic keratoconjunctivitis is not fully
understood, but investigators have proposed a complex
immunomodulatory dysfunction at the ocular surface,
including type I and type IV hypersensitivity reactions52 53
with a predominantly Th1 cytokine profile, perhaps because
of the chronicity of the disorder.54
Currently available therapies are aimed, at best, at relieving
symptoms; there is no evidence for a significant effect on the
disease course. Corticosteroids are the mainstay of treatment,
with dramatic improvement in acute symptoms. However,
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the efficacy of steroids in preventing the crippling con-
sequences of atopic keratoconjunctivitis is not known.
Corneal complications are seen in up to 60% to 70% of
patients.49 55 Despite a combination treatment with topical
mast cell stabilisers + oral antihistamines + intermittent
topical corticosteroid, about 30% of patients require corneal
transplantation for visual or tectonic purposes.49 Also,
resistance to topical steroids may necessitate systemic CsA
therapy.56
In two prospective, randomised, double masked, placebo
controlled trials, topical CsA was found to be an effective and
safe treatment in both steroid dependent and steroid
resistant cases of atopic keratoconjunctivitis.57 58 In the earlier
study,57 21 patients used either topical 2% CsA or the vehicle
alone four times daily for 3 months, in addition to their usual
therapy with topical corticosteroids and/or mast cell stabi-
lisers. The great majority of the treated patients were able to
discontinue their topical steroid treatment. The later study58
included 20 patients with topical steroid resistant, severe
atopic keratoconjunctivitis; they had moderately active
disease despite topical steroid therapy with or without mast
cell stabilisers. Treatment (CsA or placebo) lasted for 28 days
with a dosing schedule of six times daily during the first
2 weeks and four times daily during the last 2 weeks.
Significant improvement was observed in the CsA group,
and none of these patients had a worsening of the disorder,
in contrast with the placebo group.
Another study involving both atopic keratoconjunctivitis
and vernal keratoconjunctivitis patients who had experienced
no improvement with conventional therapy documented the
beneficial effect of topical CsA as an additive treatment, with
a reduced need for topical steroid use.59
Laboratory studies of the immunomodulatory effects of
topical CsA in atopic keratoconjunctivitis have shown
decreased numbers of leucocytes and CD4+ and IL-2 receptor
positive T cells in conjunctival biopsy specimens of subjects
with atopic keratoconjunctivitis following therapy.60
Topical CsA seems to be an effective steroid sparing agent
in patients with severe atopic keratoconjunctivitis. However,
its efficacy as a first line agent during long term treatment
warrants additional studies.
NON-INFECTIOUS KERATITIS
Immune mediated, sterile central or paracentral corneal
ulceration may develop in patients with connective tissue
disease, most commonly in rheumatoid arthritis or Sjögren’s
disease. These conditions need to be distinguished from
peripheral ulcerative keratitis (PUK), because PUK is
essentially a vasculitis of limbal blood vessels and is
considered to be associated with (re)activation of systemic
illness.61 Central ulcerations or keratolysis, by contrast, are
not associated with a limbal vasculitis.62
Immunohistochemical studies demonstrated infiltration with
macrophages, T lymphocytes, and aberrant expression of HLA
class II antigens, suggesting a cellular immune reaction
targeted at the cornea.63 64
The treatment should be aimed at stopping melting and
encouraging re-epithelialisation. In severe cases, with corneal
melting and perforation, tissue adhesives may be used.
Controlling the underlying illness is essential. However,
unlike PUK, the central/paracentral ulcerations may not
respond well to systemic immunosuppressive therapy.64 65
Several small, uncontrolled case series have reported the
beneficial effect of topical CsA in treating paracentral corneal
ulcers associated with connective tissue disease. In one study,
topical 2% CsA, four times daily, was instituted in five
patients with unilateral paracentral rheumatoid corneal
ulceration who had not responded to systemic immunosup-
pression.64 Treatment resulted in an immediate arrest of
keratolysis and re-epithelialisation. In another study, sys-
temic immunosuppressive therapy either could not be
initiated owing to a systemic contraindication or was
discontinued because of side effects in five patients with
collagen vascular diseases.65 The patients were treated with
topical 2% or 0.5% CsA, four to six times daily. All but one of
the eyes responded favourably with an intense neovascular-
isation within 48 hours of initiating treatment. In other small
series sterile marginal corneal ulcers in the context of
rheumatoid arthritis responded to use of 2% CsA eye drops
twice daily with healing of the ulcers within several days.63 66
Observation of macrophages, T lymphocytes, and aberrant
expression of HLA class II antigens in the corneal and
conjunctival tissues of patients with immune corneal ulcers
associated with collagen vascular disorders suggests a cellular
immune reaction. However, the current clinical evidence
supporting the role of topical CsA in the treatment is weak.
THYGESON’S SUPERFICIAL PUNCTATE KERATITIS
Thygeson’s superficial punctate keratitis is a bilateral,
idiopathic epithelial keratitis characterised by recurrent
attacks of tearing, photophobia, blurred vision, and foreign
body sensation.67 The classic finding is multiple corneal
epithelial lesions that appear during the exacerbations of the
disease.68 Although clinical features are similar to those of
viral infections, responsiveness to corticosteroids suggests an
immune process, perhaps a post-infectious delayed hyper-
sensitivity.69 However, no infectious aetiology has yet been
found.70
Mild cases are often treated with lubricants and bandage
lenses.71 72 More symptomatic cases are generally treated with
weak topical steroids.68 Recurrences are common following
the cessation of therapy. Some patients may require regular
steroid use for years.68
Reports have indicated that most patients with Thygeson’s
superficial punctate keratitis respond to topical CsA.73–75 In
more than two thirds of the patients, topical CsA suppressed
the epithelial and subepithelial opacities as long as the drug
was administered. Recurrences occurred during the tapering
off period. In one third of patients this therapy seemed to be
curative. The results are encouraging and suggest that topical
CsA may be a safe alternative to corticosteroids for the
treatment of Thygeson’s superficial punctate keratitis, parti-
cularly for patients who will require long term topical steroid
treatment.
LIGNEOUS CONJUNCTIVITIS
Ligneous conjunctivitis is a rare form of chronic conjunctivitis
characterised by the development of firm, fibrin rich, woody-
like pseudomembranous lesions mainly on the tarsal
conjunctiva.76 Cornea may be involved secondarily, with
scarring and vascularisation.
The disorder is generally bilateral, and the onset is
frequently during childhood.77 The pseudomembranes are
characterised by subepithelial deposition of amorphous
hyaline material; a cellular component composed of lympho-
cytes, plasma cells, neutrophils, eosinophils, and mast cells;
and neovascularisation. The amorphous material has been
shown to contain fibrin(ogen), immunoglobulins, and
albumin, suggesting an increased permeability of blood
vessels.77 Histopathological findings from affected humans
and (plasminogen deficient) mice indicate that wound
healing, mainly in injured mucosal tissues, is impaired
because of markedly decreased (plasmin mediated) extra-
cellular fibrinolysis.78 Rare immunohistochemical studies
have revealed a predominance of T cells,79 80 particularly with
IL-2 receptor expression. The management of ligneous
conjunctivitis is difficult, and no satisfactory treatment
exists.
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Several small, uncontrolled case series of CsA therapy have
indicated improvement in patients with ligneous conjuncti-
vitis that is refractory to other modes of treatment.79 81
However, contradictory reports also exist.80
LICHEN PLANUS
Lichen planus is an inflammatory dermatosis of unknown
aetiology that affects the skin and mucous membranes.
Classic lesions appear as recurrent, violaceous, pruritic
papules distributed symmetrically on the flexor surfaces of
the extremities and trunk. These lesions are often accom-
panied by lesions of the oral, genital, and, rarely, ocular
mucosa.82 Conjunctival lichen planus, albeit rare, can lead to
irreversible damage to the ocular surface and loss of vision
from corneal scarring.83 84
Although the pathogenesis is not fully understood, current
findings suggest an autoimmune process mediated by T cells
infiltrating the basement membrane and the basal layers of
epithelium.
Most patients with skin involvement can be treated
successfully with topical corticosteroids. Chronic, aggressive
lesions may need additional therapy ranging from psoralen
plus ultraviolet A to retinoids or CsA.85 Low dose systemic
CsA may be required for patients with severe disease
unresponsive to systemic steroids.86
Reported treatments of conjunctival lichen planus include
CsA, mycophenolate mofetil, and azathioprine used systemi-
cally.83 87 Because of its ability to accelerate apoptosis in
fibrotic tissues,88 topical CsA alone was used in a few patients
having conjunctival involvement from lichen planus, and
proved effective in controlling inflammation and scarring.84 89
In particular, patients with isolated lichen planus of the
conjunctiva may be candidates for topical CsA treatment with
or without topical corticosteroids.90
SUPERIOR LIMBIC KERATOCONJUNCTIVITIS
Superior limbic keratoconjunctivitis is a chronic, local ocular
surface disease characterised by episodes of recurrent inflam-
mation of the upper palpebral and superior bulbar conjuncti-
vae, as well as of the superior limbus and cornea.91 The classic
finding of this condition is bilateral local hyperaemia of the
superior bulbar conjunctiva. Patients often complain of
burning, foreign body sensation, and photophobia. The exact
pathophysiology is unknown. A mechanical theory proposed
soft tissuemicrotrauma between tarsal and bulbar surfaces and
between conjunctival stroma and sclera.92
Topical CsA was reported to be helpful as a primary or
adjunctive therapy for superior limbic keratoconjunctivitis in
a single study involving five patients.93 In patients with
concomitant dry eye and superior limbic keratoconjunctivitis,
topical CsA may be used for both increasing tear production
and controlling inflammation.
LESS COMMON USES OF TOPICAL CICLOSPORIN A
There are also several, unconfirmed small case series or case
reports on the use of topical CsA in the treatment of Mooren’s
ulcer,94 Cogan syndrome,95 chronic sarcoidosis of the conjunc-
tiva,96 conjunctival manifestations of actinic prurigo,97 keratitis
of Senter syndrome (keratitis-ichthyosis deafness),98 delayed
onset bilateral diffuse lamellar keratitis after laser in situ
keratomileusis,99 and microcrystalline keratopathy caused by
streptococcus.100 However, the evidence seems inadequate to
justify the use of topical CsA in these conditions.
CONCLUSIONS
Topical CsA has been used in ophthalmology since the early
1980s. Based on the available evidence, CsA eye drops seem
to be safe. No serious side effects were reported with the
0.05%, 0.5%, or 2% preparations, used for periods of up to
12 months. Current literature supports the efficacy of topical
CsA in the treatment of various ocular surface disorders,
particularly the dry eye syndrome and severe allergic
keratoconjunctivitis. Future studies should be directed to
comparing the efficacy of topical CsA with that of corticos-
teroids and to its ability to change the natural course of some
of these disorders during longer term follow up.
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